Zak was down in the dumps today, so I cheered him up by blathering on for ten minutes about the curent red hot M&A market. Here is the link to today's session:
Hacks at the FT last night landed a rather good scoop about Pfizer winning the long running Medivation auction with a $14 billion takeover bid. Here is the link:
http://www.ft.com/cms/s/0/0b556924-67e5-11e6-a0b1-d87a9fea034f.html#axzz4Hzh24lte..
I see Bloomberg was today badgering Dr Severin Schwan, the Roche chief executive, into providing a denial to my BioMarin story from a few weeks ago.
According to the Bloomberg story I read today, Dr Schwan said Roche was looking at small to medium-sized acquistions although he believes biotech valuations are "too high" even after the recent market correction...
Swiss pharmaceuticals giant Roche has once again been studying a multi-billon dollar purchase of American rare disease specialist BioMarin Pharmaceutical, according to two sources familiar with the matter.
I understand that, so far, the majority of work and analysis on BioMarin has been carried out by Roche's own executives, led by Boris Zaitra, head of M&A...
French pharmaceutical giant Sanofi is working on a back up plan in case it fails to win its $9.3 billion hostile pursuit of US-listed Medivation.
Top sources have told me the French pharmaceutical giant has begun looking at US-based rare disease specialist BioMarin Pharmaceutical as a potential alternative takeover deal after growing frustrated in its pursuit of Medivation, which has so far resisted the French company's advances...